跳到正文
原文
Nature Biotechnology· Songtao Dong·· 2026-09-28AI 评分21

针对大 RNA 载荷与组织靶向优化的脂质纳米颗粒增强体内基因组编辑

Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing

AI 导读

一项研究对脂质纳米颗粒(LNP)进行优化,以装载大尺寸 RNA 载荷并实现组织靶向,从而提升体内基因组编辑效果。该工作聚焦 LNP 递送大 RNA 货物与组织选择性这一递送瓶颈,属于递送载体层面的研究进展,尚处实验研究阶段。

正文
  1. Villiger, L. et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nat. Rev. Mol. Cell Biol. 25, 464–487 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Pacesa, M., Pelea, O. & Jinek, M. Past, present, and future of CRISPR genome editing technologies. Cell 187, 1076–1100 (2024).

    Article  CAS  PubMed  Google Scholar 

  3. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chemello, F., Olson, E. N. & Bassel-Duby, R. CRISPR-editing therapy for Duchenne muscular dystrophy. Hum. Gene. Ther. 34, 379–387 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xu, W., Zhang, S., Qin, H. & Yao, K. From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine. J. Transl. Med. 22, 1133 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Leonard, A. & Tisdale, J. F. A new frontier: FDA approvals for gene therapy in sickle cell disease. Mol. Ther. 32, 264–267 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806–2827 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther. 6, 53 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hanlon, K. S. et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun. 10, 4439 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620–628 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dong, B., Nakai, H. & Xiao, W. Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 18, 87–92 (2010).

    Article  CAS  PubMed  Google Scholar 

  14. Ryu, S. M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536–539 (2018).

    Article  CAS  PubMed  Google Scholar 

  15. Truong, D. J. et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 43, 6450–6458 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kohn, D. B., Chen, Y. Y. & Spencer, M. J. Successes and challenges in clinical gene therapy. Gene Ther. 30, 738–746 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl Acad. Sci. USA 121, e2307796121 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).

    Article  CAS  PubMed  Google Scholar 

  20. Polack, F. et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Baden, L. indsey et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

    Article  CAS  PubMed  Google Scholar 

  22. Kazemian, P. et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol. Pharm. 19, 1669–1686 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gillmore, J. ulian et al. Nexiguran ziclumeran gene editing in hereditary ATTR with polyneuropathy. N. Engl. J. Med. 393, 1375–1386 (2025).

    Article  CAS  PubMed  Google Scholar 

  24. Zheng, L., Bandara, S. R., Tan, Z. & Leal, C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc. Natl Acad. Sci. USA 120, e2301067120 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Garaizar, A. et al. Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments. Proc. Natl Acad. Sci. USA 121, e2404555121 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z. & Blakney, A. K. Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach. Mol. Pharm. 19, 1892–1905 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410–1415 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chen, J. et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc. Natl Acad. Sci. USA 120, e2309472120 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Xu, Y. et al. Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery. Proc. Natl Acad. Sci. USA 122, e2409572122 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).

    Article  CAS  PubMed  Google Scholar 

  33. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).

    Article  CAS  PubMed  Google Scholar 

  34. Yu, S. Y. et al. A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. Mol. Ther. 31, 1159–1166 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wolter, J. M. et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature 587, 281–284 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Buiting, K., Williams, C. & Horsthemke, B. Angelman syndrome—insights into a rare neurogenetic disorder. Nat. Rev. Neurol. 12, 584–593 (2016).

    Article  CAS  PubMed  Google Scholar 

  37. Binici, B., Rattray, Z., Zinger, A. & Perrie, Y. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: a combined in vitro and preclinical perspective. J. Control. Release 377, 162–173 (2025).

    Article  CAS  PubMed  Google Scholar 

  38. Cheng, M. H. Y. et al. Liposomal lipid nanoparticles for extrahepatic delivery of mRNA. Nat. Commun. 16, 4135 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).

    Article  CAS  PubMed  Google Scholar 

  40. Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 310, 173–186 (2001).

    Article  CAS  PubMed  Google Scholar 

  41. Xue, Y. et al. Lipid nanoparticles enhance mRNA delivery to the central nervous system upon intrathecal injection. Adv. Mater. 37, 2417097 (2025).

    Article  CAS  Google Scholar 

  42. Cao, D. et al. Lipid nanoparticles for mRNA delivery in brain via systemic administration. Sci. Adv. 11, eadw0730 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A. & Sahay, G. Strategies for non-viral vectors targeting organs beyond the liver. Nat. Nanotechnol. 19, 428–447 (2024).

    Article  CAS  PubMed  Google Scholar 

  44. Loughrey, D. & Dahlman, J. E. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13–23 (2022).

    Article  CAS  PubMed  Google Scholar 

  45. Bentz, J., Ellens, H., Lai, M. Z. & Szoka, F. C. On the correlation between HII phase and the contact-induced destabilization of phosphatidylethanolamine-containing membranes. Proc. Natl Acad. Sci. USA 82, 5742–5745 (1985).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bao, X. et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct. Target. Ther. 9, 13 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  47. Vendrely, K. M., Kumar, S., Li, X. & Vaughan, A. M. Humanized mice and the rebirth of malaria genetic crosses. Trends Parasitol. 36, 850–863 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Stone, D. et al. Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice. Mol. Ther. Methods Clin. Dev. 33, 101470 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dong, S. et al. A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death. Nat. Nanotechnol. 20, 1856–1870 (2025).

    Article  CAS  PubMed  Google Scholar 

  51. Marks, A. et al. mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03099-z (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  52. Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).

    Article  PubMed  Google Scholar 

  53. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Xue, L. et al. Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. Nat. Nanotechnol. 20, 132–143 (2025).

    Article  CAS  PubMed  Google Scholar 

  56. Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Wang, C. et al. Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. 24, 1653–1663 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Dong, S. et al. Biodegradable lipid nanoparticles for genome editing in the brain via intrathecal administration. Mater. Today 92, 140–150 (2026).

    Article  CAS  Google Scholar 

  59. Gong, F. et al. Amino acid-derived ionizable lipids enable inhaled base editing for therapeutic gene correction in the lung. Nat. Mater. https://doi.org/10.1038/s41563-026-02555-0 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  60. Schlich, M. et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 6, e10213 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Álvarez-Benedicto, E. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater. Sci. 10, 549–559 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  62. Gruner, S. M., Cullis, P., Hope, M. & Tilcock, C. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu. Rev. Biophys. Biophys. Chem. 14, 211–238 (1985).

    Article  CAS  PubMed  Google Scholar 

  63. Frolov, V. A., Shnyrova, A. V. & Zimmerberg, J. Lipid polymorphisms and membrane shape. Cold Spring Harb. Perspect. Biol. 3, a004747 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  64. Kobierski, J., Wnętrzak, A., Chachaj-Brekiesz, A. & Dynarowicz-Latka, P. Predicting the packing parameter for lipids in monolayers with the use of molecular dynamics. Colloids Surf. B 211, 112298 (2022).

    Article  CAS  Google Scholar 

  65. Hurley, A. & Lagor, W. R. Treating cardiovascular disease with liver genome engineering. Curr. Atheroscler. Rep. 24, 75–84 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Pankowicz, F. P. et al. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat. Commun. 7, 12642 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Ferrari, S., Geddes, D. M. & Alton, E. W. F. W. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv. Drug Deliv. Rev. 54, 1373–1393 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ramalho, A. S. et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 27, 619–627 (2002).

    Article  CAS  PubMed  Google Scholar 

  70. Alapati, D. & Morrisey, E. E. Gene editing and genetic lung disease. Basic research meets therapeutic application. Am. J. Respir. Cell Mol. Biol. 56, 283–290 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Fell, C. W. et al. Reprogramming site-specific retrotransposon activity to new DNA sites. Nature 642, 1080–1089 (2025).

    Article  CAS  PubMed  Google Scholar 

  73. Chen, Y. et al. All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposons. Cell 187, 4674–4689 (2024).

    Article  CAS  PubMed  Google Scholar 

  74. Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239–250 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

来源:Nature Biotechnology · nature.com